- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03208907
DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil (CuraVivax)
An Open Label Randomized Comparative Study to Assess the Efficacy and Tolerability of Eurartesim® Versus Chloroquine and Nonrelapse Therapy With Primaquine for Uncomplicated Plasmodium Vivax Monoinfection Malaria
Study Overview
Status
Conditions
Detailed Description
Dihydroartemisinin/Piperaquine (DHA-PQP or Eurartesim®) is recommended by World Health Organization Expert Board for the treatment of P.vivax malaria, in case of chloroquine-resistance (CQR). However, no clinical study has been conducted to assess the efficacy of DHA-PQP in P.vivax malaria in the Americas. According a study performed in Amazonas state, Brazil, Artesunate/Amodiaquine (ASAQ) exhibited high efficacy against CQ resistant Plasmodium vivax and is an adequate alternative in the study area. They recommend other studies with an efficacious comparator, longer follow-up and genotype-adjustment can improve CQR characterization. Other publication, a meta-analysis of randomized controlled trials, found nine publications from January 1989 to May 2013 in which DHA-PQP was more efficacious than CQ and Artemether/Lumefantrine in treating uncomplicated P. vivax malaria. However, this drug combination is not active against the hypnozoite stage of P. vivax. So, more efforts are required to establish how best combine this treatment with appropriate nonrelapse therapy.
In 2015, primaquine was assessed in high dose for 14 days as treatment for the hypnozoite forms with DHA-PQP or artesunate-pyronaridine (AS-PYR). Both the treatment arms offer evidence of good tolerability and efficacy.
In other previous study performed in an area with high chloroquine-resistance (Southern Papua, Indonesia), DHA-PQP was compared to ASAQ, but never compared to chloroquine by itself in areas where chloroquine still works. The objectives of this trial are to demonstrate the superiority of adequate parasitological response at D42 of Dihydroartemisinin plus Piperaquine versus Chloroquine and to evaluate the proportion of failure until D180 considering different starting days of Primaquine (0.50 mg/kg/day) for 14 days.
This clinical trial will be undertaken in the Amazonas State (Western Brazilian Amazon), in Manaus, at Fundação de Medicina Tropical Dr Heitor Vieira Dourado. The climate is tropical, with mean temperatures between 26°C and 30°C. It is a prospective, open-label, 4-arm, randomized and comparison trial. One hundred and fifteen (115) patients were planned to be enrolled in each treatment arm (after a preliminary analysis this number was increased to 184; total number of participants: 563). In this protocol, all the subjects will be screened to evaluate Glucose-6-phosphate dehydrogenase deficiency (G6PD) deficiency and the laboratorial tests (specially haemoglobin) in all the visits will be evaluated, as well. The referred deficiency is estimated to be 3% among men from the Amazon and essentially the A-type (african type), which leads to moderate deficiency and minor clinical complications. Each dose of the schizonticidal treatment will be administered by a study pharmacist, and the patient will be monitored for 30 minutes after administration. The assessment schedule will be done in days 1, 2, 3, 5, 7, 14, 21, 28, 42, 63, 90, 120, 150 and 180 (in addition, patient will be asked to come back to the health centre if fever occurs at any time).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Amazonas
-
Manaus, Amazonas, Brazil, 69040000
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
1 Inclusion criteria:
- Adults and children over 6 months old (bodyweight>5 kg)
- Body weight ≥5 kg and <100 kg (or above, upon justification of the investigator);
- Biologically confirmed symptomatic Monoinfection by Plasmodium vivax, with parasite density between 100 and 100,000;
- Efficient activity of the enzyme Glucose-6-Phosphate Dehydrogenase (G6PD);
- Conditions for oral treatment;
- Plans known to remain in the area of the research center during the follow-up period (180 days);
- Hemoglobin concentration (Hb) at baseline> 7g / dL.
- Women with reproductive potential (defined as women who are not in postmenopausal dust for at least 24 consecutive months, ie without menstruation within 24 months of admission to the study, and women who have not undergone surgical sterilization, specifically hysterectomy or bilateral oophorectomy) must have a negative pregnancy test or urine test within 48 hours prior to admission to the study; NOTE: The history reported by the participant is considered acceptable documentation of hysterectomy, bilateral oophorectomy, and menopause. Women are considered menopausal if they have not had a menstrual period for at least 12 months and have had a follicle-stimulating hormone (FSH) greater than 40 IU/L; if the FSH test not available, they must be in amenorrhea for 24 or more consecutive months. For women of child-bearing age, provision is made for using contraceptives as described in research product and primaquine information. Contraceptives should preferably be used at least two weeks prior to the start of study drug and continued for least one week after the discontinuation of any drug from the study. In case the patient reports that she has not used any contraceptive method in the two weeks prior to inclusion, she may be included if the doctor discards the possibility of pregnancy;
- If the patient engage in sexual activity that could lead to pregnancy, women should use a form of contraception. At least one of the following methods should be used properly:
Condoms (male or female) with or without spermicidal agent; Diaphragm or cervical cap with spermicide Intrauterine device (IUD) Hormonal contraceptive Ligation Tubal microimplants i. Women with no reproductive potential, as defined above, are without the use of contraceptives.
j. Ability and willingness of the participant or legal guardian to provide free and informed consent in writing. Children who are able to understand the goals and risks of the study will sign a consent form.
2. Non-inclusion criteria:
a. Participate in another ongoing clinical trial; b. Signs of severe malaria such as: recent history of seizures (1-2 within 24 hours), unconscious state, lethargy, inability to drink or breastfeed, constant vomiting, inability to get up / sit due to weakness; c. Known hypersensitivity to any of the experimental medicinal products or to any of the excipients d. Evidence or report of ingestion of antimalarial treatment in the 60 days prior to inclusion; e. Concomitant or underlying serious illness, such as porphyria or psoriasis or known disturbances of electrolyte balance, such as hypokalemia or hypomagnesemia; f. Liver function test with ALT> 3x the reference value, which, according to the researcher's assessment, endangers the safety of the participant;
3. Exclusion criteria:
- Withdrawal of consent;
- The researcher's opinion, based on the risk and benefit assessment of the study;
- Detection of mixed infection by malaria;
- Women who become pregnant by the 63rd day of follow-up;
- Women of childbearing age who give up using effective contraception during the first 63 days of follow-up study;
- Discontinuation of blood schizonticidal treatment for any reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CQ coadministered with PQ
Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine was administered for 14 days (0.50mg/kg/day)
|
113 subjects in a 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
Other Names:
|
Experimental: DHA-PQP coadministered with PQ
Dihydroartemisinin/Piperaquine was administered according to the weight and Primaquine (0.50mg/kg/day)
|
In this treatment group, 112 subjects took DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
Other Names:
|
Experimental: CQ and PQ starting on Day 42
Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine started on Day 42 for 14 days (0.50mg/kg/day) [arm halted after preliminary analysis]
|
98 subjects in a 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
Other Names:
|
Experimental: DHA-PQP and PQ starting on Day 42
Dihydroartemisinin/Piperaquine was administered for 3 days according to the weight and Primaquine started on Day 42 for 14 days (0.50mg/kg/day) [arm halted after preliminary analysis]
|
95 subjects in a 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with negative parasitological test (schizonticidal therapy evaluation)
Time Frame: Day 42
|
Schizonticidal efficacy will be assessed based on the absence of Vivax Plasmodium parasites in blood of the participants, confirmed by microscopy.
|
Day 42
|
Number of participants with negative parasitological test (nonrelapse therapy evaluation)
Time Frame: Day 180
|
Nonrelapse therapy efficacy will be assessed based on the absence of Vivax Plasmodium parasites in blood, confirmed by microscopy.
|
Day 180
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with negative parasitological test
Time Frame: 6 months (for this analysis will not be considered the primary outcomes dates (Day42 and D180)
|
Therapy efficacy will be assessed based on the presence or absence of Vivax Plasmodium parasites in blood, confirmed by the presence or absence of parasites in peripheral blood by microscopy.
|
6 months (for this analysis will not be considered the primary outcomes dates (Day42 and D180)
|
Number of participants with any biological intolerability
Time Frame: Until Day 28
|
Evolution of haemoglobin levels until D28 will be monitored in all the scheduled visits and also on unscheduled visits.
|
Until Day 28
|
Number of participants with any treatment-related adverse event of clinical tolerability
Time Frame: 6 months
|
The participants will be clinically monitored.
In all the scheduled visits a study physician will evaluate and register the clinical exam, and also obtain and update the clinical history to describe any adverse event.
The participants will have also a card with a 24h phone number to contact in case of clinical symptoms or others needing.
|
6 months
|
Number of participants with treatment-related prolonged QT interval.
Time Frame: Day 3
|
Electrocardiogram evaluation will be assessed after completion of schizonticidal treatment
|
Day 3
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marcus VG de Lacerda, MD, PhD, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAAE: 69476017.3.0000.0005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria, Vivax
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordMenzies School of Health ResearchCompletedUncomplicated Vivax MalariaAfghanistan, Ethiopia, Indonesia, Vietnam
-
Centers for Disease Control and PreventionTerminated
-
Menzies School of Health ResearchMinistry of Health, MalaysiaUnknownPlasmodium Vivax Malaria Without ComplicationMalaysia
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchAga Khan University; University of Melbourne; Universitas Sumatera Utara; Ethiopian... and other collaboratorsRecruitingVivax Malaria | Malaria, Vivax | Plasmodium Vivax | Malaria RelapseCambodia, Ethiopia, Indonesia, Pakistan
-
Menzies School of Health ResearchUniversity of Melbourne; Curtin University; Addis Ababa University; Fundação de... and other collaboratorsNot yet recruitingVivax MalariaBrazil, Ethiopia, Indonesia, Papua New Guinea
-
University of OxfordCompleted
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompletedMalaria | Vivax MalariaPakistan
Clinical Trials on CQ coadministered with PQ
-
Shanghai Municipal Center for Disease Control and...China National Biotec Group Company LimitedNot yet recruitingMeasles | Rubella | Mumps | Varicella | SARS-CoV-2 InfectionChina
-
Imperial College LondonWexham GI TrustCompleted
-
London School of Hygiene and Tropical MedicineBEIJING HOLLEY-COTEC PHARMACEUTICALS CO. LTD.Completed
-
Indonesia UniversityCompleted
-
Ministry of Health, BhutanMenzies School of Health Research; Asia Pacific Malaria Elimination NetworkUnknown
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompleted
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle GlaucomaUnited States
-
National Institute on Drug Abuse (NIDA)GlaxoSmithKlineCompleted
-
Armauer Hansen Research Institute, EthiopiaUnited States Agency for International Development (USAID); Tulane University; Addis Continental Institute of Public Health and other collaboratorsUnknown
-
Professor Francois VenterUniversity of Cape TownCompletedTuberculosis | HIV-1-infectionSouth Africa